Member Info for VertizeaSun

If AS still dreams about emulating Roche etc he better move quickly and put Therapeutics on Nasdaq and leave diagnostics on AIM. It's bad luck but we are now in the wrong part of the economic cycle (understatement) and probably our only chance of a real return is hoping Myles McNulty is right and Avacta gets sold before Christmas.

I didn't think it required explaining. Of course I meant increasing by 90p. What do you think will happen? What are your numbers?

The SP will fly about 90p before it's sold into. It only needs a few dozen day-dream traders...that's the problem with AIM. No liquidity.

Not the whole story. The real prize is TMAC and for that you need Leeds University invented Affimer.

From 1st September when the high was 134.5. It's all in the small print.

This status grants Avacta some big tax breaks in the States. Which would be useful if the company had a Nasdaq listing!

So what exactly is the difference between Waiting Approval and Designated?

Date Designated: 09/01/2022
Orphan Designation: Treatment of soft tissue sarcoma
Orphan Designation Status: Designated

Myles stated - quite recently - that Avacta would be T/O before the end of 2022. If it's not then it doesn't leave much room for settling finance for the last half of 2023. Which moves us straight on to 3996 and Takeda. DE will get shoved aside.

The dog days of summer. 5th September and it should perk up.....how about a Nasdaq listing to put a smile on our collective.